Sector News

SK bioscience and Thailand’s GPO enter MoU to boost vaccine response

July 7, 2023
Life sciences

South Korea-based SK bioscience and the Thailand state-owned pharmaceutical company the Government Pharmaceutical Organisation (GPO) have entered a memorandum of understanding (MoU) to bolster vaccine infrastructure in Thailand.

The deal will enhance the country’s pandemic response system, aiming to produce Thailand’s vaccines locally. It will then be expanded to the wider southeast Asian region.

The two companies will support vaccine development and manufacturing capabilities in Thailand, working together closely in the mid-to-long-term to support the country as a vaccine hub in southeast Asia.

SK bioscience will transfer its cell culture-based influenza vaccine’s production and manufacturing technology to the GPO’s facility.

Following this technology transfer, SK bioscience will provide the vaccine’s processes to the Thai company, which will seek marketing authorisation from the regulators.

The vaccines produced will be used for the national vaccination drive in Thailand.

GPO managing director Dr Mingkwan Suphannaphong stated: “A MoU-signing ceremony between GPO and SK bioscience today substantially contributes to a collaboration on manufacturing the cell-culture based influenza vaccine locally in Thailand, namely the trivalent and quadrivalent inactivated influenza vaccines.

“The drug substance bulk produced by SK will be initially delivered to GPO prior to making the drug products.”

In June 2023, SK bioscience and the Peter Doherty Institute for Infection and Immunity entered a research partnership to develop a next-generation influenza vaccine.



comments closed

Related News

October 1, 2023

Clinical data from Boston Scientific and rivals could reshape pulmonary embolism market: analysts

Life sciences

After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.

October 1, 2023

AstraZeneca and SAS link up on AI and analytics

Life sciences

SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.

October 1, 2023

Will Big Pharma engage in Medicare price negotiations? Merck, AZ and BMS say they will

Life sciences

After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.

How can we help you?

We're easy to reach